The Camptothecins: Unfolding Their Anticancer Potential

, by Liehr, Joachim G.; Giovanella, Beppino C.; Verschraegen, Claire F.

Write a Review

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

ISBN: 9781573312912 | 1573312916
Cover: Hardcover
Copyright: 12/1/2000

Sorry, this item is currently not available.

Supplemental Materials

Introduction

Joachim G. Liehr

Beppino Giovanella

Keynote Lecture

Mechanism of Action of Camptothecin.

(10)

Leroy F. Liu

Shyamal D. Desai

Tsai-Kun Li

Yong Mao

Mei Sun

Sai-Peng Sim

Part I. Mechanism of Action of Camptothecins

Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins. Perspective for the Development of New Topoisomerase I Inhibitors.

(16)

Kurt W. Kohn

Yves Pommier

Dependence of Anticancer Activity of Camptothecins on Maintaining Their Lactone Function.

(9)

B.C. Giovanella

N. Harris

J. Mendoza

Z. Cao

J. Liehr

J.S. Stehlin

Camptothecin Design and Delivery Approaches for Elevating Anti-Topoisomerase I Activities in Vivo.

(10)

Thomas G. Burke

David Bom

Mechanisms of Resistance to Camptothecins.

(10)

Ahamed Saleem

Troy K. Edwards

Zeshaan Rasheed

Eric H. Rubin

Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins

Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I.

(9)

James J. Champoux

Mechanisms of DNA Topoisomerase I-Induced Cell Killing in the Yeast Saccharomyces cerevisiae.

(11)

Paola Fiorani

Mary-Ann Bjornsti

Camptothecins as Probes of the Microenvironments of Topoisomerase I - DNA Complexes.

(16)

Sidney M. Hecht

Part III. Novel Topoisomerase I Inhibitors

Preclinical and Clinical Trials of Topoisomerase Inhibitors.

(8)

Nagahiro Saijo

Homocamptothecins: E-Ring Modified CPT Analogues.

100

(12)

Olivier Lavergne

Daniele Demarquay

Philip G. Kasprzyk

Dennis C.H. Bigg

The Cascade Radical Annulation Approach to New Analogues of Camptothecins. Combinatorial Synthesis of Silatecans and Homosilatecans.

112

(10)

Dennis P. Curran

Hubert Josien

David Bom

Ana E. Gabarda

Wu Du

Part IV. New Camptothecin Derivatives and Formulations

Structure-Activity Relationship of Alky1 Camptothecin Esters.

122

(14)

Zhisong Cao

Panayotis Pantazis

John Mendoza

Janet Early

Anthony Kozielski

Nick Harris

Dana Vardeman

Joachim Liehr

John S. Stehlin

Beppino Giovanella

Conjugation of Camptothecins to Poly-(L-Glutamic Acid).

136

(15)

Jack W. Singer

Peter de Vries

Rama Bhatt

John Tulinsky

Peter Klein

Chun Li

Luka Milas

Robert A. Lewis

Sidney Wallace

9-Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice.

151

(13)

Vernon Knight

Eugenie S. Kleinerman

J. Clifford Waldrep

Beppino C. Giovanella

Brian E. Gilbert

Nadezhda V. Koshkina

Modified Lactone/Carboxylate Salt Equilibria in Vivo by Liposomal Delivery of 9-Nitro-Camptothecin.

164

(11)

Diana S-L. Chow

Ling Gong

Michael D. Wolfe

Beppino C. Giovanella

New Analogues of Camptothecins. Activity and Resistance.

175

(3)

Epie Boven

Annemarie H. Van Hattum

Ilse Hoogsteen

Hennie M.M. Schluper

H.M. Pinedo

Intraperitoneal Topoisomerase-I Inhibitors. Preliminary Findings with 9-Aminocamptothecin.

178

(10)

Franco Muggia

Leonard Liebes

Milan Potmesil

Anne Hamilton

Howard Hochster

Gila Hornreich

Joan Sorich

Andrea Downey

Heather Wasserstrom

Part V. Pharmacology

Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein. Potential Clinical Implications.

188

(7)

Jan H.M. Schellens

Marc Maliepaard

Rik J. Scheper

George L. Scheffer

Johan W. Jonker

Johan W. Smit

Jos H. Beijnen

Alfred H. Schinkel

Pharmacokinetics of Orally Administered Camptothecins.

195

(10)

Elora Gupta

Viral Vyas

Farheena Ahmed

Patrick Sinko

Thomas Cook

Eric Rubin

Metabolism of CPT-11. Impact on Activity.

205

(11)

Laurent P. Rivory

Pharmacology of Camptothecin Esters.

216

(8)

Joachim G. Liehr

Nick J. Harris

John Mendoza

Ahmed E. Ahmed

Beppino C. Giovanella

Part VI. Clinical Trials I, Newer Analogues

The Clinical Development of 9-Aminocamptothecin.

224

(13)

Chris H. Takimoto

Rebecca Thomas

Alternative Administration of Camptothecin Analogues.

237

(10)

C.F. Verschraegen

K. Jaeckle

B. Giovanella

V. Knight

B.E. Gilbert

Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies.

247

(13)

Miloslav Beran

Hagop M. Kantarjian

DX-895 1f: Summary of Phase I Clinical Trials.

260

(14)

R. De Jager

P. Cheverton

K. Tamanoi

J. Coyle

M. Ducharme

N. Sakamoto

M. Satomi

M. Suzuki

Part VII. Clinical Trials II, Combination Therapy

Cellular and Molecular Responses to Topoisomerase I Poisons. Exploiting Synergy for Improved Radiotherapy.

274

(19)

Shigeki Miyamoto

Tony T. Huang

Shelly Wuerzberger-Davis

William G. Bornmann

John J. Pink

Colleen Tagliarino

Timothy J. Kinsella

David A. Boothman

In Vitro Antitumor Activity of 9-Nitro-Camptothecin as a Single Agent and in Combination with other Antitumor Drugs.

293

(5)

Ralph J. Bernacki

Paula Pera

Peter Gambacorta

Yseult Brun

William R. Greco

p53 and p21 Are Major Cellular Determinants for DNA Topoisomerase I-Mediated Radiation Sensitization in Mammalian Cells.

298

(3)

Allan Y. Chen

Paul B. Scruggs

Ling Geng

Mace L. Rothenberg

Dennis E. Hallahan

Part VIII. Poster Papers

The Homocamptothecin, BN 80927, Is a Potent Topoisomerase I Poison and Topoisomerase II Catalytic Inhibitor 1.

301

(2)

Daniele Demarquay

Helene Coulomb

Marion Huchet

Laurence Lesueur-Ginot

Jose Camara

Olivier Lavergne

Dennis Bigg

The Dual Topoisomerase Inhibitor, BN 80927, Is Highly Potent against Cell Proliferation and Tumor Growth.

303

(3)

Marion Huchet

Daniele Demarquay

Helene Coulomb

Philip Kasprzyk

Mark Carlson

Jeffrey Lauer

Olivier Lavergne

Dennis Bigg

Ubiquitin, Sumo-1, and UCRP in Camptothecin Sensitivity and Resistance.

306

(3)

Shyamal D. Desai

Yong Mao

Mei Sun

Tsai-Kun Li

Jiaxi Wu

Leroy F. Liu

A Spectrophotometric Study of the pH-Dependent and DNA Binding Properties of Topotecan.

309

(5)

Steven E. Miller

Daniel S. Pilch

Kinetics of in Vitro Hydrolysis of Homocamptothecins As Measured by Fluorescence.

314

(3)

D. Chauvier

I. Chourpa

D.C.H. Bigg

M. Manfait

The Combinatorial Synthesis of Racemic Homosilatecan Libraries via a Cascade Radical Annulation.

317

(3)

Wu Du

Ana E. Gabarda

David Bom

Dennis P. Curran

Combined Radiation and 9-Nitrocamptothecin (Rubitecan) in the Treatment of Locally Advanced Pancreatic Cancer.

320

(4)

K.R. Kemp

J.G. Liehr

B. Giovanella

Preclinical and Phase I Clinical Studies with Ckd-602, a Novel Camptothecin Derivative.

324

(2)

J.H. Lee

J.M. Lee

K.H. Lim

J.K. Kim

S.K. Ahn

Y.J. Bang

C.I. Hong

Action of Topoisomerase Targeting Drugs on Non-Hodgkin's Lymphoma and Leukemia. Correlation of Clinical and Cell Culture Studies.

326

(4)

J.S. Nair

R. Kancherla

K. Seiter

F. Traganos

Y.-C. Tse-Dinh

Improvement of Therapeutic Index of Low-Dose Topotecan Delivered per os.

330

(4)

Graziella Pratesi

Michelandrea De Cesare

Franco Zunino

Camptothecin Dose, Schedule, and Timing of Administration for Clinical Radiation Sensitization.

334

(6)

Tyvin A. Rich

Alexander V. Kirichenko

Rapid Chromatin Reorganization Induced by Topoisomerase I-Mediated DNA Damage.

340

(3)

Mei Sun

Pu Duann

Chin-Tai Lin

Hui Zhang

Leroy F. Liu

NF-B Activation in Topoisomerase I Inhibitor-Induced Apoptotic Cell Death in Human Non-Small Cell Lung Cancer.

343

(2)

Masahiro Tabata

Ram Ganapathi

Phase I Study of 9-Nitro-20(S)-Camptothecin in Combination with Cisplatin for Patients with Advanced Malignancies.

345

(4)

C.F. Verschraegen

M. Vincent

J.L. Abbruzzese

D. Siegler

J.J. Kavanagh

E. Loyer

A.P. Kudelka

E. Rubin

Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan.

349

(3)

C.F. Verschraegen

C. Levenback

M. Vincent

J. Wolf

M. Bevers

E. Loyer

A.P. Kudelka

J.J. Kavanagh

Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs.

352

(3)

C.F. Verschraegen

B.E. Gilbert

A.J. Huaringa

R. Newman

N. Harris

F.J. Leyva

L. Keus

K. Campbell

T. Nelson-Taylor

V. Knight

Inhibition of DNA Replication in Camptothecin-Treated Cells Is Regulated by Protein Kinases.

355

(5)

Xiang-Yang Zhou

Ya Wang

Part IX. Concluding Remarks

Concluding Remarks.

360

(1)

Claire Verschraegen

Index of Contributors

361

Please wait while the item is added to your bag...

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

The Camptothecins: Unfolding Their Anticancer Potential

Table of Contents

Supplemental Materials